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Objectives: The disease alveolar echinococcosis (AE), caused by the larval stage of the cestode Echinococcus
multilocularis, is fatal if treatment is unsuccessful. Current treatment options are, at best, parasitostatic, and
involve taking benzimidazoles (albendazole, mebendazole) for the whole of a patient’s life. In conjunction
with the recent development of optimized procedures for E. multilocularis metacestode cultivation, we
aimed to develop a rapid and reliable drug screening test, which enables efficient screening of a large
number of compounds in a relatively short time frame.
Methods: Metacestodes were treated in vitro with albendazole, the nitro-thiazole nitazoxanide and 29 nitaz-
oxanide derivatives. The resulting leakage of phosphoglucose isomerase (PGI) activity into the medium
supernatant was measured and provided an indication of compound efficacy.
Results: We show that upon in vitro culture of E. multilocularis metacestodes in the presence of active drugs
such as albendazole, the nitro-thiazole nitazoxanide and 30 different nitazoxanide derivatives, the activity of
PGI in culture supernatants increased. The increase in PGI activity correlated with the progressive degeneration
and destruction of metacestode tissue in a time- and concentration-dependent manner, which allowed us to
perform a structure–activity relationship analysis on the thiazolide compounds used in this study.
Conclusions: The assay presented here is inexpensive, rapid, can be used in 24- and 96-well formats and will
serve as an ideal tool for first-round in vitro tests on the efficacy of large numbers of antiparasitic compounds.
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Introduction
Echinococcus multilocularis is a cestode parasite, the metaces-
tode (larval) stage of which causes alveolar echinococcosis
(AE), a mainly hepatic disease in humans. AE is fatal if not
treated appropriately. The benzimidazoles albendazole and
mebendazole are presently used for chemotherapeutic treat-
ment alone, or prior to and post-surgery. However, in AE these
benzimidazoles do not appear to be parasiticidal in vivo. In
addition, failures in drug treatments as well as the occurrence
of side effects have been reported, leading to discontinuation
of treatment or to progressive disease. Therefore, new drugs
are needed to cure AE.1,2
One approach to identify novel and/or chemotherapeutically
interesting compounds has been to perform whole organism
screening employing in vitro cultured metacestodes.1 The more
recent advances in the in vitro culture of E. multilocularis meta-
cestodes3 have been instrumental in this respect and have
allowed the culture and maintenance of metacestodes in the
laboratory on a much larger scale than described previously.4
The effects of in vitro drug treatment can be assessed mainly
by visual inspection of morphological alterations and by light
microscopy. Scanning electron microscopy (SEM) and trans-
mission electron microscopy (TEM) have also been used to inves-
tigate tissue damage in more detail,5 – 8 and nuclear magnetic
resonance (NMR) spectroscopy has been applied to investigate
metabolic changes imposed upon the parasites by drug treat-
ments.5 Others have attempted to assess parasite viability and
growth by the quantification of the expression of molecular
marker genes such as 14-3-3 and II/3-10.9 However, visual
inspection relies on subjective observations and requires experi-
enced personnel, and other techniques such as SEM, TEM, NMR
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spectroscopy and real-time RT–PCR are intrinsically time
consuming and expensive. Nevertheless, these approaches
have led to the identification of compounds with reasonable
activities in the micromolar range in vitro, including potentially
promising drugs such as the thiazolide nitazoxanide8,10 originally
developed as an antihelmintic,11 – 13 genistein derivatives,6
2-methoxyestradiol, artesunate and dihydroartemisinin,7,14 and
p38 mitogen-acivated protein (MAP) kinase inhibitors.15 While
combinations of some of these drugs with albendazole have
led to slightly improved treatment efficacy in experimentally
infected mice, none of these compounds has exhibited improved
activities compared with albendazole (reviewed in Hemphill and
Mu¨ller1 and Hemphill et al.2). Thus, many more drugs and/or
compound classes should be investigated and there is an
urgent need for a reliable, but also easy-to-handle and rapid in
vitro drug screening assay for the identification of chemothera-
peutically interesting compounds in vitro.
The rationale of our study is that such an assay could be based
on the detection of vesicle fluid components, which are released
by the metacestodes once they are structurally impaired by
drug treatment. E. multilocularis metacestodes are basically fluid-
filled vesicles that are surrounded by an outer, acellular laminated
layer, and the inner surface of this laminated layer is delineated by
the actual parasite tissue, the germinal layer. The germinal layer
secretes the components of the laminated layer towards the
metacestode periphery into the laminated layer and also secretes
and/or releases metabolites into the vesicle fluid. One enzyme
that represents an intrinsic component of vesicle fluid, and
which is also found on the laminated layer, is alkaline phospha-
tase (AP).16,17 The detection of AP activity in medium super-
natants of drug-treated metacestode cultures has been
proposed as a method to screen for active drugs.18 AP activity
has indeed been found to be increased in culture supernatants
treated with nitazoxanide,8 2-methoxyestradiol and artemisinin
derivatives,7,14 but the sensitivity of this assay is not always satis-
factory.15 Thus, detection of AP activity does not represent a
reliable measure for in vitro drug screening.
Here, we present an assay, which is based on the detection of
phosphoglucose isomerase (PGI) activity, thus of a key enzyme of
glycolysis. Interestingly, PGI activity was detected not only in
cells, but also in the vesicle fluid of intact metacestodes, and
not in medium supernatants of intact vesicles. Upon mechanical
damage or in vitro drug treatment, metacestodes release PGI
into the medium supernatant and the corresponding activity
can be easily measured. In addition, we present the screening
results obtained with a series of 30 thiazolides in order to
show the potential of this screen for high-throughput assays.
Materials and methods
Media and biochemicals
If not stated otherwise, all culture media were purchased from Gibco-BRL
(Zurich, Switzerland) and biochemical reagents were from Sigma (St
Louis, MO, USA).
In vitro cultivation of E. multilocularis metacestodes
Culture of E. multilocularis (isolate H95) was carried out as described pre-
viously.3,19 In short, metacestodes dissected from experimentally infected
BALB/c mice were crushed by pressing through a metal tea strainer. The
metacestodes were incubated in antibiotic solution [20 mg/L levofloxacin
(Aventis, Meyrin, Switzerland) and 20 mg/Lciprofloxacin (Bayer, Zu¨rich, Swit-
zerland) in PBS] overnight. The next day, 5106 rat hepatocytes/mL (kindly
provided by Klaus Brehm, Institute for Hygiene and Microbiology, University
of Wu¨rzburg) were added to 1 mL of metacestodes, and medium [Dulbec-
co’s modified Eagle’s medium, 10% fetal calf serum (FCS), 100 U/mL peni-
cillin G, 100 mg/L streptomycin sulphate, 10 mg/L tetracycline-HCl and
20 mg/L levofloxacin] was added to 50 mL. These co-cultures were incu-
bated in culture flasks at 378C and 5% CO2, with medium changes once a
week. Splitting of cultures was carried out when a total metacestode
volume of 15 mL was exceeded. Metacestodes were used for experimental
procedures when they reached diameters of 2–4 mm.
In vitro drug treatment of E. multilocularis metacestodes
E. multilocularis metacestodes were collected at 1–2 months of culture
and were washed three times in PBS (Fluka Chemie, Buchs, Switzerland)
in order to remove medium, debris and broken vesicles. Medium without
phenol red (RPMI, 100 U/mL penicillin G and 100 mg/L streptomycin sul-
phate) was added to the same volume of vesicles and distributed to
24-well plates (Greiner Bio-One, Frickenhausen, Germany; 2 mL per
well, 25–35 vesicles) or 96-well plates (Greiner Bio-One; 200 mL per
well, 4–6 vesicles), respectively. Nitazoxanide and other thiazolides
were prepared as stocks of 10 g/L in DMSO. Pre-dilutions to 500 mg/L
were prepared in medium and added to the metacestodes as indicated.
As a negative control, the corresponding dilution of DMSO was used. As a
positive control, in some experiments, albendazole was applied. After the
indicated periods of drug treatments in vitro, damage was observed by
eye and classed into the following groups: 0, ,10%; 1, 10%–50%; 2,
50%–90%; and 3, .90% of damaged metacestodes. Samples of
medium supernatants (200 mL out of wells from 24-well plates and
100 mL out of wells from 96-well plates, respectively) were collected
and stored at 2208C until further measurement of PGI activity.
PGI assay
Damage of vesicles was measured indirectly by detecting the release of
PGI, a prominent component of vesicle fluid. PGI activity was measured
by employing an indirect assay described by Gracy and Tilley.20 The
assay was performed in 96-well microtitre plates (Greiner Bio-One). Per
well, 95 mL of assay buffer [100 mM Tris-HCl (pH 7.6), 0.5 mM NAD
(Fluka), 2 mM EDTA (Merck) and 1 U of glucose-6-phosphate dehydrogen-
ase] was mixed with 20 mL of each sample (medium supernatants, see
above). Measurements were performed in triplicate. As an assay inhi-
bition control, 5 mg/L of each compound was added to a reaction
mixture including metacestode fluid. The reaction was started by
addition of fructose-6-phosphate (Fluka) to a concentration of 1 mM.
NADH formation was measured by reading the absorbance at 340 nm
(A340) at various timepoints (0–20 min) on a 96-well plate reader
(MRXII, Dynex, Chantilly, VA, USA). Enzyme blanks (without addition of
substrate) and substrate blanks (without enzyme) were also included.
Absorbance values of these blanks were subtracted from the enzyme
reaction values afterwards. Enzyme activities were calculated from the
corresponding linear regression parameters (DA340/Dt) and expressed
as mmol substrate transformed per s (mkat). For the determination of
specific PGI activity when mechanically destroyed vesicles were com-
pared with drug-damaged vesicles, the protein content of the super-
natant was determined.
SEM and TEM
For some drug treatments, metacestodes were processed for SEM and
TEM as described by Hemphill and Croft.21 Briefly, metacestodes were
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fixed in 2.5% glutaraldehyde in 100 mM sodium cacodylate buffer (pH
7.2) for 2 h at room temperature, followed by post-fixation in 2% OsO4
in 100 mM sodium cacodylate buffer (pH 7.2) for 2 h at room tempera-
ture. Then, samples were washed in distilled water and treated with
1% uranyl acetate for 30 min. Subsequently, the specimens were exten-
sively washed in distilled water and dehydrated by sequential incubations
in increasing concentrations of ethanol. For SEM analysis, dehydrated
specimens were finally immersed in hexamethyl-disilazane and air
dried under a fume hood. They were then sputter-coated with gold
and inspected on a JEOL 840 scanning electron microscope operating
at 25 kV. For TEM, the specimens were fixed and dehydrated as described
above and subsequently embedded in Epon 812 resin (Fluka). Polymeriz-
ation of the resin was carried out at 658C overnight. Sections were cut on
a Reichert and Jung ultramicrotome and were loaded onto 300-mesh
copper grids (Plano GmbH, Marburg, Germany). Staining with uranyl
acetate and lead citrate was performed as previously described.21
Statistics
Linear regression, correlation analysis (Pearson, Spearman), analysis of
variance (ANOVA) and t-tests were performed using the software
package R version 2.8.0.22
Results
In preliminary experiments, PGI activity was identified in vesicle
fluid of E. multilocularis metacestodes. In order to see whether
the amount of PGI activity depended on metacestode size—and
thus age—metacestodes were kept in culture for different time
periods, divided into four size classes (size 1, ,2 mm; size 2, 2–
4 mm; size 3, 4–6 mm; and size 4, .6 mm) and identical
volumes of vesicle fluid were assessed for PGI activity. PGI activity
was even detectable in fluids of the smallest metacestodes and
significantly correlated to size (P,0.05, Figure 1). For further
experiments, metacestodes of 2–4 mm in diameter were used.
In order to investigate whether drug-induced structural
damage of metacestodes leads to release of vesicle fluid com-
ponents into the medium supernatant, we treated metacestodes
with nitazoxanide (5 mg/L for 4 days). This resulted in distinct
alterations within the metacestode tissue as assessed by TEM,
including loss of microtriches, accumulation of lipid droplets and
progressive disintegration of tissue organization (Figure 2a and
b). The release of PGI activity into the medium supernatant was
measured and compared with the activity obtained from mechani-
cally lysed metacestodes and with DMSO as a solvent control
(Figure 2c). Whereas PGI release from DMSO-treated vesicles was
barely detectable, specific PGI activity from nitazoxanide-treated
and mechanically destroyed vesicles was nearly 50 times higher.
Both values were significantly different from the DMSO value, but
not from each other (Figure 2c). Thus, release of PGI activity corre-
lated with drug-induced metacestode tissue damage.
Time course experiments were performed. Metacestodes
were incubated with albendazole (5 mg/L), nitazoxanide
(5 mg/L) or DMSO (as a solvent control) for 10 days. At various
timepoints, PGI activity in the medium supernatants was
measured. DMSO did not lead to an increase of PGI activity in
medium supernatants. In the case of nitazoxanide, PGI activity
increased from 3 days onwards, reaching a plateau between
day 5 and day 10 of drug treatment. In the case of albendazole,
5 days of treatment did not lead to a substantial PGI release,
while after 10 days PGI activity levels in albendazole-treated cul-
tures were similar to those obtained with nitazoxanide treatment
(Figure 3). The increase in PGI activities was clearly linked to
the morphological damage caused by these two drugs, while
in the DMSO treatment controls alterations of metacestode
morphology were not observed (data not shown).
In order to assess this in more detail, and to show that the PGI
assay could be a useful screening tool for assessing the efficacy of
drugs in vitro, metacestodes were incubated with a set of 30 thia-
zolides with modifications on the thiazole and/or the salicylic acid
moiety (see Figure 4 and Table 1). PGI activity was measured in
parallel to a visual classification of metacestode damage
assessed by eye using a scoring system as indicated (Table 1).
First, none of the drugs investigated here interfered in the
functional activity of PGI (data not shown). Secondly, there
was a highly significant correlation between the degree of
morphological damage and the PGI activity released into the
supernatant (rank correlation according to Spearman, r¼0.917,
P¼1.510213). Interestingly, not only nitro compounds such as
nitazoxanide, RM4802, RM4805 and RM4807, but also haloge-
nated molecules such as RM4827, RM4830, RM4831, RM4835
and RM4838-RM4841 exhibited enhanced PGI activity values
and morphologically detectable damage already after 5 days of
treatment. Treatments with other halogenated thiazolides such
as RM4804, RM4806, RM4819, RM4820, RM4822, RM4834,
RM4836, RM4842 and RM4843 showed evidence of antiparasitic
activities only after 10 days of treatment (data not shown).
In order to analyse structure–function relationships in more
detail, the non-nitro-thiazolides were grouped with respect to
the halogenations of the thiazole and the salicyl moieties of
the thiazolide molecule, and the corresponding PGI activities
were analysed by ANOVA (Figure 5). The analysis showed that
halogenations not only of the thiazole moiety (P¼0.0056),
but also of the salicyl moiety (P¼0.0061) were significantly
correlated with metacestodicidal activity (Figure 5).
In order to investigate the most highly active thiazolides
in more detail, the nitro-thiazolide RM4807 and the tribromo-





















Figure 1. PGI activity in vesicle fluid of E. multilocularis metacestodes of
various size classes, namely: ,2 mm (1); 2–4 mm (2); 4–6 mm (3); and




series experiment. Metacestodes were cultured in 24-well plates
and treated with increasing concentrations (0.1–10 mg/L) of
these compounds for 5 days (Figure 6). At concentrations of 5
and 10 mg/L, PGI activity levels were high for both compounds.
At a concentration ,5 mg/L, the nitro-thiazolide RM4807 was no
longer effective, and PGI activity was not detectable at a drug
concentration of 1 mg/L (Figure 6). On the other hand, the
tribromo-thiazolide RM4841 did induce vesicle fluid leakage at
concentrations as low as 0.5 mg/L. Given the different molecular
weights of RM4807 (281) and RM4841 (416), the concentrations
with half maximal activity, as calculated after logit-log (RM4807;
P¼0.008) or log transformation (RM4841; P¼0.003) followed by
regression analysis, were 10.6 (standard error 3.9) mM and 2.4
(1.2) mM, respectively. In the same assay, albendazole had no
effect on PGI release after 5 days. After 10 days, metacestodes
treated with albendazole were damaged, and released PGI with
a half-maximal activity at 5.6 (0.1) mg/L corresponding to 21.1
(0.4) mM as calculated by linear regression analysis from the
data (P¼0.007).
In order to investigate whether the screening assay
presented above could be down-scaled to a 96-well format,




























Figure 2. PGI activity correlates with drug-induced metacestode damage. (a) TEM of a control DMSO-treated metacestode. (b) Metacestode treated
with nitazoxanide (5 mg/L) for 10 days. Note the significant damage induced upon nitazoxanide treatment. The bar in (a)¼1.6 mm and the bar in
(b)¼1.4 mm. LL, laminated layer; TE, tegument; GL, germinal layer; mt, microtriches; ld, lipid droplets. (c) PGI activity in the medium of
metacestodes grown for 10 days in the presence of nitazoxanide (NTZ; 5 mg/L), in the medium of metacestodes grown for 10 days in the
presence of the corresponding amount of DMSO as a solvent control (Control) or in the medium of control metacestodes after mechanical
destruction (MD). Means+SE are given.
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for metacestodicidal activities, 2–4 mm size class metacestodes
were transferred to a 24-well plate and to a 96-well plate in the
presence of nitazoxanide (5 mg/L) as described. After 5 days, PGI
activity in the supernatants of 7 randomly selected wells of the
24-well plate and of 12 randomly selected wells of the 96-well
plate was measured, the mean values and the variances were
determined and the coefficient of variation was calculated. The
mean values in both formats were not significantly different
(P.0.05) and the coefficients of variation were similar, namely
0.25. Thus, this screen can easily be adapted to 96-well
formats suitable for high-throughput screenings (Table 2).
When the screen described above was repeated in 96-well
plates, the results obtained were correlated to the results
obtained in 24-well plates with a high significance (regression
according to Pearson, P¼3.31028).
Discussion
PGI activity is a marker that indicates drug-induced
metacestode damage in vitro
Previous studies have shown that in vitro drug treatment of
E. multilocularis metacestodes could represent a valuable tool
for the investigation of chemotherapeutically interesting com-
pounds with respect to their antiparasitic activities including
drug uptake studies by HPLC, NMR studies of metabolic altera-
tions induced through drug treatment and the investigation of
ultrastructural changes imposed through drugs.4 – 8,14,15
However, when it comes to performing drug testing assays
with a multitude of chemotherapeutically interesting reagents,
these techniques suffer from their complexity or require large
amounts of parasite material. TEM is helpful but time consuming,
and only a small portion of the metacestode can be investigated
using the electron microscope. Thus, a practical and reliable
assay for monitoring parasite damage is required for monitoring
the effects of drugs on parasite structural integrity and viability.
Here, we present such an assay that allows assessment of the
antiparasitic efficacy of chemotherapeutically interesting com-
pounds against E. multilocularis metacestodes. PGI is an abun-
dant component of the metacestode vesicle fluid, but it is not
secreted into the medium by intact parasites. Once damage
occurs and the parasites suffer from structural impairment,
metacestodes lose turgor, leakage of vesicle fluid into the
medium supernatant occurs and PGI activity is thus readily
detected. The levels of enzymatic activity upon drug treatment
correlate well with the morphological alterations observed visu-
ally (inspection by eye, SEM and TEM) and activity levels rose in
a dose- and time-dependent manner. This assay can be
performed in 24- and 96-well plates, yielding essentially identical
results, and is thus suitable for reliably screening larger numbers
of compounds for metacestodicidal activity. Moreover, this assay
can be used for the investigation of time- and concentration-
dependent drug effects in a more quantifiable and standardiz-
able way than methods based on morphological investigations.
Structure–activity relationship of thiazolides
With the PGI assay described here, we have investigated the
structure–activity relationship of a group of anti-infective thiazo-
lides, a drug family with activities against a broad spectrum of
parasites and tumour cells.13,23 – 28 For helminths, as well as for
anaerobic bacteria and protozoa, the mode of action of nitazox-
anide, the mother compound of the family,12 has been proposed
to be related to the presence of the thiazole-associated nitro
group (see, for example, Hemphill et al.27), but detailed investi-
gations have been lacking. For anaerobic microorganisms such
as Campylobacter jejuni, Helicobacter pylori or Giardia lamblia,
the mode of action is thought to be linked to the inhibition of pyr-
uvate ferredoxin oxidoreductase (PFOR) activity through interfer-
ence with its co-factor thiamine pyrophosphate.29 Moreover,
Pankuch and Appelbaum30 compared the activities of nitazoxa-
nide and tizoxanide with five other thiazolides against anaerobic
bacteria and showed that only compounds that carried a
nitro-thiazole were active in vitro, while bromo derivatives were
not. Other studies in G. lamblia also demonstrated that
only nitro-thiazolides exhibited profound antigiardial activity
in vitro,31 and identified a novel nitroreductase (GLNR1) as a
potential target.32 PFOR and NR are, however, lacking in E. multi-
locularis. In contrast, investigations on intracellular parasites such
as Neospora caninum showed that the activity of nitazoxanide
was independent of the nitro-thiazole group, and bromo com-
pounds were also effective against this parasite in vitro.23– 25 In






















Figure 3. Release of PGI activity into the growth medium of
E. multilocularis metacestodes is time dependent. Metacestodes were
incubated for up to 10 days in the presence of nitazoxanide (NTZ;
5 mg/L), albendazole (ABZ; 5 mg/L) or the corresponding amount of












Figure 4. Core structure of the thiazolides. R1–R4, X and Y of the
compounds used in this study are indicated in Table 1.
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proliferation of normal human cells such as foreskin fibroblasts
in vitro, and are toxic towards colon cancer cells.28
Our screen has revealed that not only nitro-thiazolides, but
also halogenated thiazolides, are effective against metaces-
todes. The presence of halogens, both on the thiazole and on
the salicyl moieties of the thiazolide backbone is significantly cor-
related with high activity. The most promising compound for
further investigations on antiechinococcocal activity is RM4841,
a tribromo-thiazolide. When compared with albendazole,
RM4841 affects metacestode integrity much more rapidly and
at a lower concentration range.
Is the mode of action of thiazolides in E. multilocularis
similar to that postulated for tumour cells?
Not only nitro- but also bromo-thiazolides inhibit the proliferation
of human Caco2 cells, whereas thiazolides with other substi-
tutions have no effects. In a pull-down study, human
glutathione-S-transferase P1 (hGSTP1) has been identified as a
thiazolide-binding protein, and the activity of recombinant
GSTP1 is inhibited by thiazolides that also inhibit cellular prolifer-
ation. Moreover, knock-down of hGSTP1 in 293T cells correlated
with lower sensitivity, and overexpression of hGSTP1 led to
higher sensitivity of the cells to thiazolides.28 In E. multilocularis,
a GST has been characterized that shares catalytic properties
with hGSTP1,33 and, based on the present results, Echinococcus
GST as a potential target should be investigated. In any case,
these findings stress the similarities between the intrinsic biologi-
cal properties of E. multilocularis metacestodes and cancer cells,
as proposed by others.34 Thus, in principle, a wide range of anti-
cancer drugs could be tested for metacestodicidal activity. The
fact that the PGI assay can also be performed in a 96-well
format suggests that this could be done at a significantly
increased rate.
AE is not regarded as one of the major parasitic diseases, and
the number of patients acquiring this infection is relatively low.
However, the consequences for the individual patient are extre-
mely severe and the disease leads to death in those patients
Table 1. Chemical structures of thiazolides used in this study
Compound X Y R1 R2 R3 R4 Damage PGI
nitazoxanide NO2 H OCOCH3 H H H 1 1.6
RM4802 NO2 H OCOCH3 CH3 H H 2 2.8
RM4803 Br H OCOCH3 CH3 H H 0 0.1
RM4804 Cl H OCOCH3 CH3 H H 1 0.6
RM4805 NO2 H OH OCH3 H H 2 1.9
RM4806 Br H OH OCH3 H H 1 0.2
RM4807 NO2 H OH H H CH3 2 1.9
RM4808 -SO2-phenyl-NO2 H OCOCH3 H H H 0 0.1
RM4819 Br H OH CH3 H H 1 1.1
RM4820 Br H OCOCH3 H H H 1 0.7
RM4821 Br H OCOCH3 H H CH3 0 0.1
RM4822 Br H OCOCH3 H CH3 H 1 0.9
RM4824 H CO2CH2CH3 OCOCH3 H H H 0 0.1
RM4827 Br H OH Cl H H 2 2.2
RM4828 NHCOCH3 H OCOCH3 H H H 0 0.3
RM4829 H Ph OH CH3 H H 0 0.2
RM4830 H Ph OH Cl H H 2 1.5
RM4831 Br H OH H F H 2 1.5
RM4833 Br H OH H OCH3 H 2 0.7
RM4834 Br H OH H H OCH3 0 0.1
RM4835 Cl H OH H OCH3 H 3 2.2
RM4836 Cl H OH H H OCH3 0 0.1
RM4837 H CH2CH2OH OH H H H 0 0.1
RM4838 Br H OH H Cl H 2 2.1
RM4839 Br H OH H H Cl 2 1.4
RM4840 Br H OH H H Br 2 1.9
RM4841 Br H OH Br H Br 3 2.4
RM4842 H Ph OH H H Br 1 0.3
RM4843 H Ph OH H H H 0 0.1
RM4844 NHCOCH3 H OH H H H 0 0.2
RM4845 NHCOCH3 OCOCH3 OCOCH3 H H H 0 0.1
The thiazolide core structure is shown in Figure 4. R1–R4 are substituents of the salicyl moiety and X and Y are substituents of the thiazole moiety.
Effects on E. multilocularis metacestodes incubated with the compounds (at 5 mg/L) in 24-well plates for 5 days are given as visual damage, namely
0, ,10%; 1, 10%–50%; 2, 50%–90%; and 3, .90% of damaged metacestodes, and activity of PGI released into the medium (mkat/mL).
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for whom chemotherapy is unsuccessful in halting parasite
growth. In addition, any drug that would improve the che-
motherapeutic treatment of AE could also produce a significant
improvement in cystic echinococcosis caused by the closely
related Echinococcus granulosus, which affects many more
patients worldwide with a significantly higher impact, similar to
what has been found for African trypanosomiasis.35 A first step
in the improvement of current therapies will be the in vitro
screening of novel reagents, and the test system based on moni-
toring PGI activity appears to be an ideal tool for studies involving
large numbers of compounds. Moreover, besides PGI and the
previously described AP, other vesicle fluid constituents could
be exploited as viability markers in a similar way.
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Figure 5. Release of PGI activity into the growth medium of
E. multilocularis metacestodes treated with thiazolides (5 mg/L; 5 days)
as described in Table 1. Thiazolides were classed with respect to the
presence or absence of halogen groups. YY, halogens on both
the thiazole moiety and the salicyl moiety; YN, halogens only on the
thiazole moiety; NY, halogens only on the salicyl moiety (only one
compound); NN, no halogens, nitro compounds within this group





















Figure 6. Release of PGI activity into the growth medium of
E. multilocularis metacestodes depends on drug concentration.
Metacestodes were incubated for 5 days in the presence of the
nitro-thiazolide RM4807, the tribromo-thiazolide RM4841, albendazole
(ABZ; 5 and 10 days; 0–10 mg/L) or the corresponding amount of
DMSO as a solvent control (values subtracted). Activities were
measured in triplicate. Means+SE are given.




Mean value 1.71 1.34
Variance 0.18 0.10
Standard deviation 0.43 0.32
Coefficient of variation 0.25 0.24
E. multilocularis metacestodes were grown for 5 days in the presence of
nitazoxanide in 96- and 24-well plates. Supernatants of 7 wells (24-well
plate) or 12 wells (96-well plate) were randomly selected, and PGI
activity was measured in the supernatant. Mean values and
parameters estimating the variation between samples are given.
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